Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 33% ± 13% | |
peripheral blood | 15 studies | 33% ± 12% | |
brain | 13 studies | 33% ± 16% | |
eye | 10 studies | 28% ± 12% | |
intestine | 9 studies | 33% ± 17% | |
kidney | 7 studies | 26% ± 6% | |
lymph node | 5 studies | 39% ± 12% | |
pancreas | 4 studies | 39% ± 19% | |
bone marrow | 4 studies | 37% ± 15% | |
uterus | 4 studies | 41% ± 15% | |
breast | 4 studies | 28% ± 5% | |
liver | 4 studies | 38% ± 16% | |
adipose | 4 studies | 30% ± 10% | |
placenta | 3 studies | 35% ± 4% | |
heart | 3 studies | 21% ± 5% | |
skin | 3 studies | 22% ± 0% | |
esophagus | 3 studies | 36% ± 28% | |
prostate | 3 studies | 22% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 7819.67 | 459 / 459 | 100% | 211.68 | 1118 / 1118 |
esophagus | 100% | 6322.88 | 1445 / 1445 | 100% | 150.86 | 183 / 183 |
intestine | 100% | 6799.73 | 966 / 966 | 100% | 165.24 | 527 / 527 |
ovary | 100% | 10813.54 | 180 / 180 | 100% | 157.36 | 430 / 430 |
stomach | 100% | 4846.65 | 359 / 359 | 100% | 150.78 | 286 / 286 |
uterus | 100% | 9523.06 | 170 / 170 | 100% | 214.35 | 459 / 459 |
thymus | 100% | 6492.63 | 653 / 653 | 100% | 188.40 | 604 / 605 |
lung | 100% | 6381.34 | 577 / 578 | 100% | 165.33 | 1155 / 1155 |
bladder | 100% | 7485.14 | 21 / 21 | 100% | 179.29 | 503 / 504 |
prostate | 100% | 5799.12 | 245 / 245 | 100% | 144.30 | 501 / 502 |
brain | 100% | 5213.29 | 2632 / 2642 | 100% | 156.65 | 705 / 705 |
pancreas | 99% | 3276.08 | 326 / 328 | 100% | 141.07 | 178 / 178 |
skin | 100% | 7959.44 | 1809 / 1809 | 99% | 163.91 | 469 / 472 |
kidney | 100% | 5157.53 | 89 / 89 | 99% | 132.84 | 890 / 901 |
liver | 100% | 2448.32 | 225 / 226 | 99% | 81.87 | 402 / 406 |
adrenal gland | 100% | 5554.90 | 258 / 258 | 97% | 94.69 | 224 / 230 |
adipose | 100% | 7575.07 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7214.93 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 214.84 | 29 / 29 |
spleen | 100% | 5795.61 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 193.25 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 82.77 | 1 / 1 |
muscle | 100% | 3617.04 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 3914.59 | 841 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 114.26 | 77 / 80 |
peripheral blood | 95% | 5968.73 | 884 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0046833 | Biological process | positive regulation of RNA export from nucleus |
GO_0007283 | Biological process | spermatogenesis |
GO_0045948 | Biological process | positive regulation of translational initiation |
GO_0006397 | Biological process | mRNA processing |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_0000086 | Biological process | G2/M transition of mitotic cell cycle |
GO_0046831 | Biological process | regulation of RNA export from nucleus |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0031647 | Biological process | regulation of protein stability |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0016020 | Cellular component | membrane |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0070618 | Cellular component | Grb2-Sos complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0008143 | Molecular function | poly(A) binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0003729 | Molecular function | mRNA binding |
GO_1990782 | Molecular function | protein tyrosine kinase binding |
GO_0042169 | Molecular function | SH2 domain binding |
GO_0035591 | Molecular function | signaling adaptor activity |
GO_0008266 | Molecular function | poly(U) RNA binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0017124 | Molecular function | SH3 domain binding |
Gene name | KHDRBS1 |
Protein name | KH domain containing, RNA binding, signal transduction associated 1, isoform CRA_b (cDNA FLJ52899, highly similar to KH domain-containing, RNA-binding, signaltransduction-associated protein 1) KH domain-containing, RNA-binding, signal transduction-associated protein 1 (GAP-associated tyrosine phosphoprotein p62) (Src-associated in mitosis 68 kDa protein) (Sam68) (p21 Ras GTPase-activating protein-associated p62) (p68) |
Synonyms | hCG_41606 SAM68 |
Description | FUNCTION: Recruited and tyrosine phosphorylated by several receptor systems, for example the T-cell, leptin and insulin receptors. Once phosphorylated, functions as an adapter protein in signal transduction cascades by binding to SH2 and SH3 domain-containing proteins. Role in G2-M progression in the cell cycle. Represses CBP-dependent transcriptional activation apparently by competing with other nuclear factors for binding to CBP. Also acts as a putative regulator of mRNA stability and/or translation rates and mediates mRNA nuclear export. Positively regulates the association of constitutive transport element (CTE)-containing mRNA with large polyribosomes and translation initiation. According to some authors, is not involved in the nucleocytoplasmic export of unspliced (CTE)-containing RNA species according to . RNA-binding protein that plays a role in the regulation of alternative splicing and influences mRNA splice site selection and exon inclusion. Binds to RNA containing 5'-[AU]UAA-3' as a bipartite motif spaced by more than 15 nucleotides. Binds poly(A). Can regulate CD44 alternative splicing in a Ras pathway-dependent manner (By similarity). In cooperation with HNRNPA1 modulates alternative splicing of BCL2L1 by promoting splicing toward isoform Bcl-X(S), and of SMN1 . Can regulate alternative splicing of NRXN1 and NRXN3 in the laminin G-like domain 6 containing the evolutionary conserved neurexin alternative spliced segment 4 (AS4) involved in neurexin selective targeting to postsynaptic partners. In a neuronal activity-dependent manner cooperates synergistically with KHDRBS2/SLIM-1 in regulation of NRXN1 exon skipping at AS4. The cooperation with KHDRBS2/SLIM-1 is antagonistic for regulation of NXRN3 alternative splicing at AS4 (By similarity). .; FUNCTION: Isoform 3, which is expressed in growth-arrested cells only, inhibits S phase. . |
Accessions | ENST00000327300.12 [Q07666-1] Q07666 ENST00000492989.1 [Q07666-3] B4E043 |